Squarepoint
AVXL icon

Squarepoint’s Anavex Life Sciences AVXL Stock Holding History

Squarepoint’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-278,800
Closed -$2.58M – 3221
2022
Q4 		$2.58M Buy
+278,800
New +$2.98M 0.01% 1214

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Squarepoint's AVXL Position: Q2 2026 in Review

Squarepoint opened a new position in Anavex Life Sciences (AVXL) in Q2 2026: 38,423 shares worth $99.5K. The stake represents ﹤0.01% of the portfolio and ranks #4204 among its holdings. This is a return to the name: Squarepoint previously reported a position in AVXL as recently as Q4 2025.

Squarepoint first reported a position in AVXL in Q1 2016 and has held it in 21 quarters since. The position peaked at $1.09M in Q3 2021. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Squarepoint held 38,423 shares of Anavex Life Sciences worth $99.5K as of Q2 2026.
  • Anavex Life Sciences was a new Squarepoint position in Q2 2026.
  • Anavex Life Sciences made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4204 holding.
  • Squarepoint first reported a position in Anavex Life Sciences in Q1 2016 and has held it in 21 quarters since.
  • Squarepoint's Anavex Life Sciences position peaked at $1.09M in Q3 2021.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.